Navigation Links
Triptolide: A Potential Drug for Polycystic Kidney Disease

KD1 or PKD2 gene causing the cells to miss the “stop growing” signal, allowing them to keep growing, and thus generating a cyst.

In collaboration with Stefan Somlo, M.D., Chief of Nephrology at Yale School of Medicine, who discovered the PKD2 gene, triptolide was tested in a mouse model of PKD. Both fewer and smaller kidney cysts formed in mice lacking PKD1 when they were treated with therapeutic amounts of triptolide.

“Our research shows that triptolide, an active ingredient of the TCM Lei Gong Teng, markedly decreases cyst formation in a mouse model of this most common genetic lethal kidney disease,” Crews said. “Our results offer a novel therapeutic approach to this deadly disease and highlight the potential of TCM as pharmaceutical sources.”


Source-YALE Univesity
SRM
'"/>




Page: 1 2

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. Potential Benefits Of New Nanotechnology
11. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
Post Your Comments:
(Date:5/12/2008)... Allied Healthcare Products,Inc. (Nasdaq: AHPI )...quarter ending March 31 fell 64 percent, from abou...ut $100,000 in the current quarter, or 1 cent per,...about $240,000 compared to the,third quarter of th...osts,this fiscal year eroded margins and profits f...
(Date:5/12/2008)...rt, of System, WASHINGTON, May 12 /PRNewswire-U...VA), the nation,s largest single employer of nurse...its top professionals., "VA nurses are the comp...stem," stated Secretary of Veterans Affairs Dr. Ja...s from the personal, one-on-one interaction,betwee...
(Date:5/12/2008)...Montreal, May 12, 2008 A team of researchers has ...il protects the heart in mice with Duchenne muscul...Des Rosiers from the Universit de Montral and the .... Basil Petrof of the Research Institute of the Mc...tian Deschepper of the Institut de recherches clin...
(Date:5/12/2008)...or the 12 weeks ended March ...ewswire-FirstCall/ -- Matrixx,Initiatives, Inc. (N...pany,that develops and markets products that provi...today announced its financial results for the four... For the fourth quarter ended March 31, 2008, the ...
Breaking Medicine News(10 mins):Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 2Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 3Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 4Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 5Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 6Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 7Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 8
...y of Texas has found that caffeine is often used t.... Sleep apnea is a condition characterized by cess...re infants. However, there is a growing concern ov...culatory system.// Researchers in Texas analyzed t...
...vels of the amino acid homocysteine may increase t... researchers report. It is still too soon to be ce...e the risk of Alzheimer's// and other types of dem...stigating. Prior research has shown that elevated ...
... York, there has been a declining trend in mortali... has increased. Researchers at the University of T...e deadliest form of skin cancer, between 1981 and ...ncrease in cases among men - from 2.0 cases per 15...
...y of Texas, offer some valuable advice on how to m... is essential for healthy bones and teeth, and hel...se. Doctors believe that natural sunlight helps th...of natural sunlight three times a week should be a...
Other Medicine News:Health News:Caffeine reduces infant blood flow 2Health News:High Levels of Protein Linked to Brain Shrinkage 2
(Date:5/9/2008)...swire/ -- Osteoarthritis is a,painful and potentia...million people in the United States. It is caused ...novel investigational pain medication,tapentadol, ...icant relief,for patients with joint-disease pain,...fewer gastrointestinal side effects than those tre...
(Date:5/9/2008)...all/ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA ), ... of,small- molecule therapeutics for the treatment...ng gout, today announced that John W. Beck,has bee...rations and Chief,Financial Officer effective May ...rs shortly thereafter. The Company also reported r...
(Date:5/8/2008)...all/ -- DATATRAK International, Inc.,(Nasdaq: DAT...global,eClinical solutions for the clinical trials...r the first quarter of 2008., For the three month...ately 41% to $2,088,000 and the Company reported a... both a basic and diluted basis. These,results com...
(Date:5/8/2008)...ial of asenapine in the treatment of ...TON, May 8 /- Schering-Plou...an overview of asenapine clinical trials,from the ...Meeting of the,American Psychiatric Association in... involving patients with bipolar I disorder and sc...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7TFAH Applauds Release of CDCs State Specific Public Health Emergency Preparedness Report 12366 1TFAH Applauds Release of CDCs State Specific Public Health Emergency Preparedness Report 12366 2Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases 3427 1Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases 3427 2Cognitive Impairment Declining in Older Adults 12363 1Cognitive Impairment Declining in Older Adults 12363 2Drinking milk may help ease the pressure 2277 1Drinking milk may help ease the pressure 2277 2
...NESS WIRE)--Apr 12, 2007 - AVEO,Pharmaceuticals, I...scovery and development of novel, targeted cancer ...total of 12 oral and poster,presentations at the A...ual Meeting on April 14-18, 2007, in Los Angeles,...e cancer community the,pioneering oncology researc...
...--The costs of eradicating,poliomyelitis from the ...ort term, are much lower than the long term costs ...n. And a recently developed,monovalent vaccine is ...oliomyelitis than an existing trivalent vaccine. T...line and in an upcoming,issue of The Lancet. , Bot...
Other Medicine Technology:AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 2AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
...tbeat. The bodys warmth beneath drapes. The life-g...ns are yours to guard, measure, stabilize and cros...roducts helps you do your job, giving you the info... precise management of your patients stability dur...
...aser system used in neurophysiology for studying e...just the amplitude and/or the duration of the stim...laser emission in an ongoing manner by acting on t...r include the high repeatability of the impulses, ...
Medicine Products: